ID :
200748
Thu, 08/11/2011 - 17:53
Auther :
Shortlink :
https://oananews.org//node/200748
The shortlink copeid
U.S. patent OK'd for iPSC technology of Kyoto Univ.'s Yamanaka
KYOTO, Aug. 11 Kyodo - The United States has approved a patent for Kyoto University professor Shinya Yamanaka's technology for creating induced pluripotent stem cells, or iPSCs, the university said Thursday.
The U.S. approval of the patent followed that in Europe in May for the technology for iPSCs that could be reprogrammed to grow into different types of tissue, such as nerve, heart and liver, and are expected to provide a revolutionary breakthrough in regenerative medicine and drug development.
Yamanaka said at a press conference that the acquisition of the patent is highly significant to remove anxiety in research and development and he hopes to advance the research to make the technology useful in clinical practices.
Over the patent in the United States, the U.S. venture iPierian Inc. also assigned its patent estate for iPSCs to Kyoto University free of charge in January to avoid a patent dispute with Yamanaka.
Kyoto University filed its application for the patent with the U.S. Patent and Trademark Office in December 2006 and received a notice of the office's decision to approve the patent last Friday.
The patent will remain in effect for about 20 years from the time the application was filed. Similar patents have been granted in Japan and other countries including South Africa and Russia.
With the parent granted, the university's intellectual property management firm will conclude license agreements with research institutes and individuals to authorize them to use the patent.
The U.S. approval of the patent followed that in Europe in May for the technology for iPSCs that could be reprogrammed to grow into different types of tissue, such as nerve, heart and liver, and are expected to provide a revolutionary breakthrough in regenerative medicine and drug development.
Yamanaka said at a press conference that the acquisition of the patent is highly significant to remove anxiety in research and development and he hopes to advance the research to make the technology useful in clinical practices.
Over the patent in the United States, the U.S. venture iPierian Inc. also assigned its patent estate for iPSCs to Kyoto University free of charge in January to avoid a patent dispute with Yamanaka.
Kyoto University filed its application for the patent with the U.S. Patent and Trademark Office in December 2006 and received a notice of the office's decision to approve the patent last Friday.
The patent will remain in effect for about 20 years from the time the application was filed. Similar patents have been granted in Japan and other countries including South Africa and Russia.
With the parent granted, the university's intellectual property management firm will conclude license agreements with research institutes and individuals to authorize them to use the patent.
